Introduction
As new therapeutic options emerge for the management of septic shock, accurate prognostic factors are needed to better identify those patients who are likely to benefit. Although a number of severity scores (including Acute Physiology and Chronic Health Evaluation II score and Simplified Acute Physiology Score [SAPS]II or SAPSIII) and biological markers (procalcitonin [PCT] and C-reactive protein, among others) are available to predict outcome in critically ill patients, the appropriateness of their use during septic shock remains debatable.
The product of growth arrest-specific gene 6 (Gas6) recently attracted attention because it was found to be elevated during sepsis and may correlate with organ dysfunction [
1]. This vitamin K dependent protein is secreted by leucocytes and endothelial cells in response to serum starvation or injury, and is the biological ligand for the Axl subfamily of receptor tyrosine kinases comprising Axl, Sky and Mer [
2]. The Gas6/Axl system participates in cell survival [
3,
4], proliferation [
5], migration [
6] and adhesion [
7]. Gas6 is also thought to act as a recognition bridge between apoptotic cells and phagocytes that ingest them [
8].
Evidence of a role for the Gas6/Axl system during sepsis has been obtained in mice. Camenisch and coworkers [
9] observed that mice that lack the intracellular domain of c-mer exhibited increased lipopolysaccharide (LPS)-induced tumor necrosis factor-α production and suffered increased mortality after LPS administration
in vivo. Moreover, the same group demonstrated that mice deficient in c-mer had impaired clearance of apoptotic cells [
10].
These data prompted us to investigate plasma concentrations of Gas6 during septic shock and its relationship with severity and outcome.
Materials and methods
Study population
Between August 2005 and February 2006, all consecutive patients admitted with septic shock into a 16-bed medical intensive care unit of a teaching hospital were enrolled. The diagnosis of septic shock was established on the basis of current definitions [
11]. Patients were not enrolled if they were older than 80 years or were immunocompromised (treatment with corticosteroids > 1 mg/kg prednisone or equivalent, bone marrow or organ transplant recipients, neutropenia < 0.5 10
9/l, haematologic malignancy, or AIDS). The institutional review board granted approval, and informed consent was obtained from patients or their relatives before their inclusion.
Data collection
Upon admission to the intensive care unit, the following items were recorded: age, sex, severity of underlying medical condition stratified according to the criteria of McCabe and Jackson, SAPSII, Sepsis-related Organ Failure Assessment (SOFA) score, vital signs, respiratory variables, routine blood tests and microbial culture results. Outcome was assessed over a 28-day follow-up period.
Measurement of sTREM-1 and Gas6 plasma concentrations
Day 1 was defined as the day of admission to the intensive care unit. Within 12 hours after admission and enrolment in the study, 5 ml whole heparinized blood was drawn via an arterial catheter for determination of soluble triggering receptor expressed on myeloid cells-(sTREM)-1 and Gas6 determinations. Assessment of plasma sTREM-1 levels was performed as described elsewhere [
12]. For Gas6 determination, microtitre plates were coated overnight at room temperature with 4 μg/ml of polyclonal mouse anti-human Gas6 antibody (RnD Systems, Lille, France). After three washes with 0.05% Tween 20 in phosphate-buffered saline, wells were blocked with 1% bovine serum albumin in phosphate-buffered saline for one hour at room temperature. Three additional washes were then performed and 100 μl plasma or standards (recombinant human Gas6; RnD Systems) were added for two hours at room temperature. Washes were repeated and 100 ng/ml biotinylated monoclonal goat anti-human Gas6 antibody (RnD Systems) added for two hours at room temperature. Detection was performed with peroxydase-conjugated streptavidin. Measurements were repeated three times, and intra-assay and inter-assay coefficients of variation were 6.3% and 7.8%, respectively.
Repeated determinations of sTREM-1 and Gas6 plasma concentrations were performed on days 1, 3, 7 and 14.
Statistical analysis
Descriptive results of continuous variables are expressed as mean ± standard deviation. Non-normally distributed values, as assessed using the Kolmogorov-Smirnov test, are reported as median (interquartile range). Correlations between Gas6 plasma concentration and clinical or biological parameters were investigated using the Spearman test. Gas6 was also tested for its association with several variables using the Mann-Whitney U test. The time course of Gas6 plasma level was assessed using analysis of variance. Analyses were completed using Statview software (Abacus Concepts, Berkeley, CA, USA), and two-tailed P < 0.05 was deemed statistically significant.
Discussion
The main finding of this study is that Gas6 plasma concentration correlates with organ dysfunction, especially that of kidney and liver, and several markers of infection during septic shock.
The product of growth arrest-specific gene 6, Gas6, is the biological ligand for the receptor tyrosine kinase Axl and is implicated in cell survival, proliferation, migration, adhesion and recognition of dying cells [
3‐
8]. Moreover, the Axl system has been shown to be essential for functional maturation of natural killer cells and normal expression of inhibitory and activating natural killer cell receptors [
13]. On one hand, Gas6 thus appears to be of crucial importance in maintaining cell function. Evidence to support this view comes from an experimental model of endotoxaemia [
9], in which mice lacking the intracellular domain of c-mer exhibited increased LPS-induced tumour necrosis factor-α production and suffered increased mortality after LPS administration
in vivo. However, in support of findings recently reported by Borgel and coworkers [
1], we observed a good correlation between Gas6 concentration and organ dysfunction during septic shock. How can these findings be reconciled?
First, because Gas6, via Akt, causes an increase in the antiapoptotic protein Bcl-2 [
14], it is tempting to link the delayed neutrophil apoptosis observed during sepsis [
15] with the concentration of this protein. An extended neutrophil life time could therefore contribute to organ injury. Although Gas6 has clearly been shown to delay cell death both
in vitro and
in vivo, this explanation remains hypothetical because we did not specifically investigate apoptosis.
Second, a deleterious role for Gas6 has been established in kidney and hepatic disease. Increased glomerular expression of Gas6 has been detected in animal models of kidney disease [
16], and Gas6 knockout mice were shown to be resistant to accelerated nephrotoxic nephritis [
17]. Gas6 upregulation was also observed during allograft rejection in a rat kidney transplant rejection model [
18] as well as in dysfunctional human renal allografts [
19]. The link between Gas6 and renal injury is indirectly supported by our finding that patients requiring renal support exhbiited increased Gas6 plasma concentrations compared with those who did not need such support. Gas6 has also been implicated during hepatic injury [
20], and we observed a correlation between Gas6 concentrations and hepatic dysfunction. Of course, it is not possible to determine here whether Gas6 is a bystander during renal and hepatic injury or directly contributes to dysfunction of these organs.
The finding that Gas6 strongly correlated with both PCT and sTREM-1 concentrations is difficult to explain. Gas6 has never shown to be a marker of infection, and neither PCT nor sTREM-1 are thought to be reliable severity markers during septic shock. Does Gas6 stimulate the release of these proteins? Although Gas6 has been shown
in vitro to stimulate nuclear factor-κB binding activity and subsequent transcriptional activation from nuclear factor-κB responsive promoters [
14,
21], this hypothesis remains to be investigated.
Because Gas6 correlated well with organ dysfunction, we sought to evaluate whether it could be used as a marker of prognosis. Admission levels of Gas6 did not differ between survivors and nonsurvivors, and this finding is in accordance with that reported by Borgel and coworkers [
1]. When patients were segregated according to outcome, we observed a divergent time course of Gas6 concentrations only at day 7 and after, and therefore Gas6 did not appear to be useful in predicting outcome during the early period of septic shock. Nevertheless, because Gas6 concentration was clearly linked to the degree of organ injury, its use as part of a panel of severity markers is interesting and could be further tested.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SG designed the study, enrolled patients, performed measurements and drafted the manuscript. FM performed measurements. AC, RD, DB and LN enrolled patients. PEB designed the study and drafted the manuscript. All authors approved the final version of the manuscript.